Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma PDF Print E-mail
Wednesday, 21 July 2010 02:56
Alexander Kreuter, MD; Thilo Gambichler, MD; Frank Breuckmann, MD; Sebastian Rotterdam, MD; Marcus Freitag, MD; Markus Stuecker, MD; Klaus Hoffmann, MD; Peter Altmeyer, MD
Arch Dermatol. 2005;141:847-852

Objective: To evaluate the efficacy of pulsed highdose corticosteroids combined with orally administered low-dose methotrexate therapy in patients with severe localized scleroderma (LS).

Design: A prospective, nonrandomized, open pilot study.

Setting: Dermatology department at a university hospital in Bochum, Germany.

Patients: Fifteen patients with histologically confirmed severe LS.

Interventions: Oral methotrexate (15 mg/wk) combined with pulsed intravenous methylprednisolone (1000 mg for 3 days monthly) for at least 6 months.

Main Outcome Measures: Treatment outcome was evaluated by means of a clinical score, 20-MHz ultrasonography, and histopathologic analysis. Safety assessment included the monitoring of adverse effects and clinical laboratory parameters.

Results: One patient discontinued therapy. In most of the remaining 14 patients, significant elimination of all signs of active disease (inflammation) and remarkable softening of formerly affected sclerotic skin that resulted in a decrease of the mean±SD clinical score from 10.9±5.3 at the beginning to 5.5±2.5 at the end of therapy was observed (P<.001). Clinical improvement was confirmed by histologic and ultrasonographic assessments. No serious adverse effects were noted.

Conclusions: These data suggest that pulsed high-dose corticosteroids combined with orally administered lowdose methotrexate therapy is beneficial and safe in the treatment of patients with LS. This treatment regimen should especially be considered for severe forms of LS
in which conventional treatments have failed.

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» Pathways In Pulmonary Arterial Hypertension

It is well established that the endothelin, nitric oxide and prostacyclin pathways play an important role in the development of pulmonary arterial hypertension (PAH). Indeed, the therapeutic options currently available for the management of PAH all...

» Scleroderma Patients At Greater Risk Of Myocardial Infarction Within First Year

According to the first large population-based cohort study of its kind, patients with Systemic Sclerosis or were found to be at a greater than eightfold increased risk of having an acute (MI) during their first year after diagnosis. After that...

» 7 Tips For Balancing Rest and Activity

I wanted to help patients and my friends by sharing some helpful tips about Scleroderma, an autoimmune disease in which the body attacks itself by destroying its own cells and functions. The effects of are quite severe and can affect a patient’s...

» Children Get Scleroderma Too

Juvenile is a rare childhood condition characterized by fibrosis of the skin and internal organs. Clinical manifestations of childhood Scleroderma are different from adult disease and early recognition, correct classification and treatment can...

» New Promising Therapy Against Systemic Sclerosis

There is a new path to defeat systemic sclerosis, also called because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent...